Two studies published in The New England Journal of Medicine describe therapies that show promise against treatment-resistant metastatic breast cancer. T-DXd shrank HER2-positive tumors by at least 30% in 61% of the treatment cohort, and tucatinib along with Herceptin and chemotherapy extended progression-free survival, including in about 25% of patients whose cancer had metastasized to the brain.
Two drugs show promise against treatment-resistant breast cancer
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.